Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Gains from Investment Securities (2020 - 2024)

Bioventus (BVS) has disclosed Gains from Investment Securities for 6 consecutive years, with $9000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Investment Securities fell 98.14% year-over-year to $9000.0, compared with a TTM value of $9000.0 through Dec 2025, down 99.37%, and an annual FY2025 reading of $9000.0, down 99.37% over the prior year.
  • Gains from Investment Securities was $9000.0 for Q3 2025 at Bioventus, down from $345000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $3.1 million in Q4 2022 and bottomed at -$3.3 million in Q4 2022.
  • Average Gains from Investment Securities over 5 years is $159875.0, with a median of $288500.0 recorded in 2023.
  • The sharpest move saw Gains from Investment Securities tumbled 750.0% in 2021, then soared 592.86% in 2024.
  • Year by year, Gains from Investment Securities stood at -$1.3 million in 2021, then plummeted by 153.64% to -$3.3 million in 2022, then soared by 108.85% to $290000.0 in 2023, then increased by 18.97% to $345000.0 in 2024, then tumbled by 97.39% to $9000.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for BVS at $9000.0 in Q3 2025, $345000.0 in Q4 2024, and $483000.0 in Q3 2024.